Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers

Smoking cessation is the only treatment in patients with chronic obstructive pulmonary disease (COPD) effective in slowing down disease progression. Its effect on airway inflammation in COPD is unknown, although cross-sectional studies suggest ongoing inflammation in ex-smokers. In order to elucidate the effect of smoking cessation on airway inflammation, 28 smokers with COPD (mean age: 55 yrs; forced expiratory volume in one second: 71% predicted) and 25 asymptomatic smokers with normal lung function (aged 50 yrs) were included in a 1-yr smoking cessation programme. Effects of smoking cessation on airway inflammation were investigated in bronchial biopsies (baseline, 12 months) and sputum samples (baseline, 2, 6 and 12 months). In the 12 candidates with COPD who successfully ceased smoking, airway inflammation persisted in bronchial biopsies, while the number of sputum neutrophils, lymphocytes, interleukin (IL)-8 and eosinophilic-cationic-protein levels significantly increased at 12 months. In the 16 asymptomatic smokers who successfully quitted, inflammation significantly reduced (i.e. number of sputum macrophages, percentage of eosinophils and IL-8 levels) or did not change. The current authors suggest that the observed persistent airway inflammation in patients with chronic obstructive pulmonary disease is related to repair of tissue damage in the airways. It remains to be elucidated whether this reflects a beneficial or detrimental effect.

[1]  D. Postma,et al.  High cessation rates of cigarette smoking in subjects with and without COPD. , 2005, Chest.

[2]  M. Cosio,et al.  Characterization of T Lymphocytes in Chronic Obstructive Pulmonary Disease , 2004, PLoS medicine.

[3]  B. Rutgers,et al.  Smoking cessation improves both direct and indirect airway hyperresponsiveness in COPD , 2004, European Respiratory Journal.

[4]  M. Cosio.  Autoimmunity, T‐cells and STAT‐4 in the pathogenesis of chronic obstructive pulmonary disease , 2004, European Respiratory Journal.

[5]  P. Paré,et al.  The nature of small-airway obstruction in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.

[6]  W. MacNee,et al.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.

[7]  D. Postma,et al.  The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation , 2004, European Respiratory Journal.

[8]  J. Erjefält,et al.  Rapid and efficient clearance of airway tissue granulocytes through transepithelial migration , 2004, Thorax.

[9]  J. Forslid,et al.  Metabolic activity in human alveolar macrophages increases after cessation of smoking , 1993, Inflammation.

[10]  M. Cosio,et al.  Hypothesis: Does COPD have an autoimmune component? , 2003, Thorax.

[11]  N. Chavannes,et al.  Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. , 2002, American journal of respiratory and critical care medicine.

[12]  John E Connett,et al.  Smoking and lung function of Lung Health Study participants after 11 years. , 2002, American journal of respiratory and critical care medicine.

[13]  W. Bailey,et al.  Editorial: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines for COPD, Including COVID-19, Climate Change, and Air Pollution , 2023, Medical science monitor : international medical journal of experimental and clinical research.

[14]  P. Hiemstra,et al.  Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD , 2000, The Journal of pathology.

[15]  A. Sousa,et al.  Subepithelial immunopathology of the large airways in smokers with and without chronic obstructive pulmonary disease. , 2000, The European respiratory journal.

[16]  T. Seemungal,et al.  Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations , 2000, Thorax.

[17]  Dirkje S Postma,et al.  Ongoing airway inflammation in patients with COPD who do not currently smoke , 1999, Chest.

[18]  G. Koëter,et al.  Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD. , 2000, The European respiratory journal.

[19]  A. Buist,et al.  Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disease: the Lung Health Study. , 1999, The American journal of medicine.

[20]  J. Pijoan,et al.  Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease. , 1999, The European respiratory journal.

[21]  L. Fabbri,et al.  Severity of airflow limitation is associated with severity of airway inflammation in smokers. , 1998, American journal of respiratory and critical care medicine.

[22]  R. Dahl,et al.  Prospective study on the effect of smoking and nicotine substitution on leucocyte blood counts and relation between blood leucocytes and lung function. , 1998, Thorax.

[23]  D. Postma,et al.  Techniques in human airway inflammation: quantity and morphology of bronchial biopsy specimens taken by forceps of three sizes. , 1998, Chest.

[24]  T. Yoneda,et al.  Airway inflammation in COPD assessed by sputum levels of interleukin-8. , 1997, Chest.

[25]  Alan D. Lopez,et al.  Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study , 1997, The Lancet.

[26]  C. Agustí,et al.  Bacterial colonization of distal airways in healthy subjects and chronic lung disease: a bronchoscopic study. , 1997, The European respiratory journal.

[27]  C. Sköld,et al.  Transient increases in albumin and hyaluronan in bronchoalveolar lavage fluid after quitting smoking: possible signs of reparative mechanisms. , 1996, Respiratory medicine.

[28]  N. Rosenthal,et al.  Immune dysregulation in the aging human lung. , 1996, American journal of respiratory and critical care medicine.

[29]  P. Barnes,et al.  Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. , 1996, American journal of respiratory and critical care medicine.

[30]  L. Fabbri,et al.  Effect of smoking cessation on airway inflammation in chronic bronchitis. , 1995, American journal of respiratory and critical care medicine.

[31]  J C Yernault,et al.  Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. , 1995, The European respiratory journal.

[32]  D. Olivieri,et al.  Mast cells in the airway lumen and bronchial mucosa of patients with chronic bronchitis. , 1994, American journal of respiratory and critical care medicine.

[33]  J. Bousquet,et al.  Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. , 1993, The Journal of allergy and clinical immunology.

[34]  J. D. de Monchy,et al.  Desensitization of the adenylyl cyclase system in peripheral blood mononuclear cells from patients with asthma three hours after allergen challenge. , 1993, The Journal of allergy and clinical immunology.

[35]  J E Cotes,et al.  Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.

[36]  R. Dahl,et al.  Serum IgE in nonatopic smokers, nonsmokers, and recent exsmokers: relation to lung function, airway symptoms, and atopic predisposition. , 1992, The Journal of allergy and clinical immunology.

[37]  C. Sköld,et al.  Smoking cessation rapidly reduces cell recovery in bronchoalveolar lavage fluid, while alveolar macrophage fluorescence remains high. , 1992, Chest.

[38]  G. Swan,et al.  Reversibility of airways injury over a 12-month period following smoking cessation. , 1992, Chest.

[39]  S. Rennard,et al.  Intraluminal airway inflammation in chronic bronchitis. Characterization and correlation with clinical parameters. , 1989, The American review of respiratory disease.

[40]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[41]  M. Murphy,et al.  Reversible alterations in immunoregulatory T cells in smoking. Analysis by monoclonal antibodies and flow cytometry. , 1982, Chest.